Stanford spent more than 20 years developing a blood-cancer transplant therapy; its first commercial patient has now been treated after a trial found 78% were free from moderate-to-severe GVHD at one year

Representative Image (AI-generated)A blood-cancer treatment that Stanford researchers have spent more than two decades developing has now reached an important milestone. Its first commercial patient has been treated following U.S. Food and Drug Administration approval. According to the Stanford Cancer Institute, the therapy, known as Orca-T, was given to a patient at Stanford Medicine outside a clinical trial.